Unicycive Therapeutics Financial Results
Unicycive Therapeutics reported third quarter 2026 financial results and provided a business update regarding its New Drug Application (NDA) for oxylanthanum carbonate (OLC). The FDA has accepted the NDA resubmission with a PDUFA target action date of March 25, 2027, following a previous Complete Response Letter related to manufacturing vendor deficiencies.
“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients. With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”
Shalabh Gupta, M.D., Chief Executive Officer